Personalized Antimicrobial Prophylaxis and Therapy via AI-Driven Peptide Design

This inventive concept leverages machine learning, synthetic biology, and genomics to develop a personalized antimicrobial prophylaxis and therapy platform, enabling tailored peptide-based treatments for individual patients and combatting antimicrobial resistance.

The original patent disclosed peptides derived from Acinetobacter baumannii for vaccination, but it had limitations in terms of scalability, adaptability, and personalized treatment. This new inventive concept addresses these limitations by integrating AI-driven design, gene editing, and synthetic biology to create a next-generation antimicrobial platform.

The inventive concept comprises a system for personalized antimicrobial prophylaxis, wherein a plurality of polypeptides derived from Acinetobacter baumannii are tailored to a specific individual's genetic profile using machine learning algorithms. Additionally, the concept includes methods for in-situ production of antimicrobial peptides in a host organism, diagnostic kits for detecting antimicrobial resistance, personalized vaccine platforms, and synthetic biology approaches to antimicrobial therapy. These components work in tandem to provide a comprehensive and adaptive solution for combating antimicrobial resistance.

The new claims introduce a paradigm shift in antimicrobial prophylaxis and therapy by integrating AI-driven design, gene editing, and synthetic biology. The inventive concept's novelty lies in its ability to provide personalized, adaptive, and scalable solutions, which are not addressed by the original patent.

Alternative embodiments of the inventive concept could include the use of different machine learning algorithms, gene editing systems, or synthetic biology approaches. Variations could also involve the application of this platform to other diseases or pathogens, or the integration of additional components, such as CRISPR-Cas systems or microbiome analysis.

The inventive concept has significant commercial potential in the pharmaceutical, biotechnology, and healthcare industries, particularly in the areas of antimicrobial resistance, personalized medicine, and synthetic biology. The target market includes pharmaceutical companies, biotech startups, and healthcare providers seeking innovative solutions to combat antimicrobial resistance.